New drug aims to tame dangerous immune reactions from cancer therapy

NCT ID NCT05306080

Recruiting now Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether an investigational drug called Tadekinig alfa can safely and feasibly treat severe immune overreactions (CRS and HLH-like syndrome) that can occur after CAR T cell therapy. Ten adult participants who are already in a CAR T cell trial will receive injections of the drug. The goal is to see if this rescue therapy can help control these serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tadekinig alfa (IL-18BP)
What this could lead to: If successful, this could provide a safer way to manage dangerous side effects from CAR T cell therapy, making the treatment more tolerable.
What could go wrong: This is a very early, small pilot study with only 10 participants, so results may not apply broadly. The drug may not effectively control CRS or HLH-like syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRS - CYTOKINE RELEASE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytokine release syndrome hemophagocytic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRS - CYTOKINE RELEASE SYNDROME HLH

Contacts and locations

Locations

University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.